Market Overview:
The global ischemic cardiomyopathy treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of ischemic cardiomyopathy, rising geriatric population, and technological advancements in the field of cardiac surgery. Based on type, the market can be segmented into medications and surgery. The medications segment dominated the global ischemic cardiomyopathy treatment market in 2017 and is projected to grow at a CAGR of 7.8% during the forecast period. This growth can be attributed to increasing use of drugs such as beta blockers, angiotensin converting enzyme inhibitors (ACE inhibitors), and angiotensin receptor blockers (ARBs) for treating patients with ischemic cardiomyopathy. Based on application, hospitals and clinics accounted for majority share of the global ischemic cardiomyopathy treatment market in 2017; however, pharmaceuticals.
Product Definition:
Ischemic cardiomyopathy is a type of heart disease that is caused by a shortage of blood flow to the heart muscle. This can lead to weakening and eventual failure of the heart muscle. Ischemic cardiomyopathy treatment focuses on improving blood flow to the heart and preventing further damage. Treatment may include medications, lifestyle changes, or surgery.
Medications:
Medications, it's usage and growth factor in Ischemic Cardiomyopathy Treatment market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of cardiovascular diseases globally. According to the American Heart Association, more than 8 million people die from cardiovascular disorders each year.
Surgery:
The global Surgery and it's usage in Ischemic Cardiomyopathy Treatment market is expected to witness significant growth over the forecast period. The key drivers attributing to the growth of this market include rising prevalence of cardiovascular diseases, increasing geriatric population base, growing healthcare awareness among people coupled with technological advancements such as minimally invasive surgeries. Moreover, favorable government initiatives pertaining to R&D for development of novel drugs are also expected to fuel the market during the forecast period.
Application Insights:
Based on application, the global ischemic cardiomyopathy treatment market is segmented into hospitals and clinics, pharmaceutical and biotechnology companies, and others. Hospitals and clinics held the largest share in 2017 owing to availability of advanced healthcare facilities along with a high number of cardiac surgeries. Moreover, these institutions offer multidisciplinary care which includes cardiology consultation for patients suffering from ISC thus contributing towards revenue growth.
The pharmaceutical industry also holds promising growth prospects due to increasing prevalence of target diseases coupled with rising demand for innovative drugs across the globe. For instance, according to data published by Boehringer Ingelheim International GmbH in 2018; around 1 billion people suffer from atrial fibrillation globally which requires regular monitoring & treatments thus driving demand for ISC drugs over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to favorable healthcare infrastructure, high adoption of advanced technologies, and availability of highly skilled cardiologists & surgeons. Moreover, increasing prevalence of ISCCM due to sedentary lifestyle and smoking is also one of the key factors contributing toward regional growth.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income; improving healthcare facilities; growing awareness about early diagnosis & treatment options for ISCCM; and supportive government initiatives pertaining towards cost-effective treatments for cardiovascular diseases (CVDs). Rising incidence rate coupled with limited treatment options available for patients suffering from sudden cardiac arrests are some other factors driving regional growth. Furthermore, rapidly developing pharmaceutical industry in emerging economies such as China & India will further boost revenue generation in this region during the forecast period (2018 - 2030).
Growth Factors:
- Increasing incidence of ischemic cardiomyopathy
- Growing awareness about ischemic cardiomyopathy and its treatment options
- Rising demand for minimally invasive procedures for ischemic cardiomyopathy treatment
- Technological advancements in the field of ischemic cardiomyopathy treatment
- increasing prevalence of cardiovascular diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Ischemic Cardiomyopathy Treatment Market Research Report
By Type
Medications, Surgery
By Application
Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others
By Companies
Amgen, Inc., Bioheart, Inc., Cytokinetics, Inc, LG Life Sciences, Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Ischemic Cardiomyopathy Treatment Market Report Segments:
The global Ischemic Cardiomyopathy Treatment market is segmented on the basis of:
Types
Medications, Surgery
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen, Inc.
- Bioheart, Inc.
- Cytokinetics, Inc
- LG Life Sciences, Ltd.
Highlights of The Ischemic Cardiomyopathy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medications
- Surgery
- By Application:
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ischemic Cardiomyopathy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one definitive answer to this question as the best treatment for ischemic cardiomyopathy will vary depending on the individual's specific situation and health condition. However, some general recommendations for treating ischemic cardiomyopathy include:nn1. Treat underlying causes of heart disease, such as high blood pressure, obesity, and diabetes. These conditions can lead to heart failure and damage to the myocardium (heart muscle).nn2. Take medications prescribed by a doctor to improve blood flow in the vessels of the heart (angiotensin converting enzyme inhibitors or angiotensin receptor blockers). These medications can help reduce inflammation and improve cardiac function in people with ischemic cardiomyopathy. In some cases, surgery may also be necessary to open blocked arteries or remove clots from coronary arteries.
Some of the key players operating in the ischemic cardiomyopathy treatment market are Amgen, Inc., Bioheart, Inc., Cytokinetics, Inc, LG Life Sciences, Ltd..
The ischemic cardiomyopathy treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ischemic Cardiomyopathy Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ischemic Cardiomyopathy Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ischemic Cardiomyopathy Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ischemic Cardiomyopathy Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ischemic Cardiomyopathy Treatment Market Size & Forecast, 2018-2028
4.5.1 Ischemic Cardiomyopathy Treatment Market Size and Y-o-Y Growth
4.5.2 Ischemic Cardiomyopathy Treatment Market Absolute $ Opportunity
Chapter 5 Global Ischemic Cardiomyopathy Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
5.2.1 Medications
5.2.2 Surgery
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ischemic Cardiomyopathy Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Pharmaceutical and Biotechnology Companies
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ischemic Cardiomyopathy Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ischemic Cardiomyopathy Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ischemic Cardiomyopathy Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Ischemic Cardiomyopathy Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
9.6.1 Medications
9.6.2 Surgery
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Pharmaceutical and Biotechnology Companies
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ischemic Cardiomyopathy Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Ischemic Cardiomyopathy Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
10.6.1 Medications
10.6.2 Surgery
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Pharmaceutical and Biotechnology Companies
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ischemic Cardiomyopathy Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ischemic Cardiomyopathy Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
11.6.1 Medications
11.6.2 Surgery
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Pharmaceutical and Biotechnology Companies
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ischemic Cardiomyopathy Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Ischemic Cardiomyopathy Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
12.6.1 Medications
12.6.2 Surgery
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Pharmaceutical and Biotechnology Companies
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ischemic Cardiomyopathy Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ischemic Cardiomyopathy Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ischemic Cardiomyopathy Treatment Market Size Forecast by Type
13.6.1 Medications
13.6.2 Surgery
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ischemic Cardiomyopathy Treatment Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Pharmaceutical and Biotechnology Companies
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ischemic Cardiomyopathy Treatment Market: Competitive Dashboard
14.2 Global Ischemic Cardiomyopathy Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen, Inc.
14.3.2 Bioheart, Inc.
14.3.3 Cytokinetics, Inc
14.3.4 LG Life Sciences, Ltd.
